Scientific Advisory Board

Robert NewmanRobert A. Newman, Ph.D., President, Chief Science Officer, Chairman of the Scientific Advisory Board, and Director. Dr. Newman obtained his M.S. and Ph.D. degrees in Pharmacology and Toxicology from the University of Connecticut and then served in postdoctoral positions at the Medical School of the University of Georgia as well as the Department of Biochemistry at the University of Vermont. He served as a faculty member at the University of Vermont Medical School for seven years and then spent a sabbatical year at Stanford University performing research on immune targeted therapy. He spent 24 years at the University of Texas M. D. Anderson Cancer Center (MDACC) in Houston, Texas where he held the D. B. Lane Distinguished Professorship Chair. At MDACC he served as the founder and Co-Director of the Pharmaceutical Development Center and the institution's Analytical Center. He has published over 320 articles dealing with the preclinical and clinical pharmacology, toxicology and development of therapies for the prevention and treatment of malignant diseases.

Donald C. LoDonald C. Lo, Ph.D., Director of the Center for Drug Discovery and Associate Professor of Neurobiology at Duke University Medical Center. Dr. Lo received his B.S. degree from the California Institute of Technology, his Ph.D. degree from Yale University, and additional postdoctoral research training at the Ludwig Institute for Cancer Research at University College London. He joined the Duke faculty in 1992, and in 1998 co-founded a biotech company, Cogent Neuroscience, Inc., focused on developing new treatments for neurodegenerative diseases of the brain including Huntington's disease, Alzheimer's disease, Parkinson's disease, and stroke. Dr. Lo returned to Duke in 2002 to establish the Center for Drug Discovery, and has been engaged in basic science and drug discovery research for neurological diseases and brain cancer for over 25 years, with numerous past and ongoing collaborations with biotech companies and major pharmaceutical firms.

Jagan SastryDr. Jagan Sastry is a Professor in the Department of immunology at The University of Texas M. D. Anderson Cancer Center, Houston, TX. His group’s research in the broad areas of viral oncology and immunology focuses on understanding the biology, pathology and genetics of two viral diseases impacting human health: HPV-associated cancers and HIV-induced AIDS. The overall goal of the research is to develop procedures and reagents for prediction, treatment as well as prevention. Over the past 25+ years Dr. Sastry has lead and/or participated in investigator initiated as well as team-oriented research programs supported by federal, state, industry, and philanthropy funds.

Dr. Sastry’s group has been testing the anti-HIV activity of various proprietary compounds from the oleander plant extract and showed for the first time anti-HIV activity of the Nerium oleander plant extract and demonstrated that this activity is related to the cardiac glycoside oleandrin with a unique mechanism of anti-HIV activity.

Dr. Sastry serves regularly as a reviewer for federal grant applications at NIH. He has been a member of The University of Texas Graduate School of Biomedical Sciences (UT-GSBS) for over 25 years and mentored several post-graduate/post-doctoral trainees and junior faculty members in the areas of virology and immunology. He provides Phoenix Biotechnology with guidance and advice regarding its antiviral research program.

Peiying YangPeiying Yang, PhD. Dr. Peiying Yang is an Associate Professor at Department of Palliative, Rehabilitation and Integrative Medicine at the University of Texas MD Anderson Cancer Center. She received her undergraduate and master degree in Pharmacy from the Beijing University of Traditional Chinese Medicine. Following a year and half of study in Department of Pharmaceutical Science at University of Kentucky, College of Pharmacy, she completed her Doctor degree in Nutritional Science from the University of Maine.

Over the past several years, Dr. Yang has been engaged in translational research of traditional Chinese medicine, natural products (oleander, toad skin, sweet gum, sweet leaf tea), and bioactive lipids (omega-3 and omega-6 metabolism) in cancer treatment and prevention through both preclinical and clinical evaluations. Additionally, more recently her laboratory has engaged in understanding the molecular mechanisms of added sugar in breast tumorigenesis. Several of her studies on natural products and cancer treatment and prevention have been funded by NIH or NCI as R01 or R21 grants. These include studies of the chemopreventive effect of fish oil on lung and colon cancer. She also serves as a key co-investigator on an NCI funded grant studying the role of Traditional Chinese Medicine in cancer treatment and symptom management. She has published more than 100 peer reviewed articles and currently serves a board member of Society of Integrative Oncology (SIO), a member of Executive Committee of SIO, and a member of American Botanical Council as well as an Associate Editor for the journal of Integrative Cancer Therapies.

George PerryGeorge Perry, Ph.D. Dr. George Perry is dean of the College of Sciences, professor of biology, and holds the Semmes Foundation Distinguished University Chair in Neurobiology at The University of Texas at San Antonio. He is recognized in the field of Alzheimer disease research, where he has studied essentially every aspect of the disease, including amyloidosis, oxidative stress, cytoskeleton, metal homeostasis, cell cycle reentry, and mitochondria. For almost 20 years, Dr. Perry has been a strong advocate for greater diversity in ideas to move the field forward.

He is distinguished as the top Alzheimer’s disease researcher by Expertscape with over 1,000 publications, one of the top 100 most-cited scientists in neuroscience and behavior, and one of the top 25 scientists in free radical research. Dr. Perry has been cited over 71,000 (H=132) times and is recognized as a Thompson-Reuters highly cited researcher. He is editor for numerous journals and is editor-in-chief for the Journal of Alzheimer's Disease, the most cited and prolific journal in Alzheimer research.